BEVACIZUMAB plus FOLFIRI AS FIRST-LINE TREATMENT IN ADVANCED COLORECTAL CANCER (ACC): A MULTICENTER PHASE II STUDY OF THE GRUPPO ONCOLOGICO DELL' ITALIA MERIDIONALE (PROT. GOIM 2601)

被引：0
|
作者：
Giuliani, F. [1 ]
Lorusso, V. [3 ]
De Vita, F. [2 ]
Cinieri, S. [4 ]
Maiello, E.
Nugnes, I. [1 ]
del Prete, S. [5 ]
Orditura, M. [2 ]
Leo, S. [3 ]
Addeo, R. [5 ]
Colucci, G. [1 ]
机构：
[1] Inst Oncol, Dept Med Oncol, Bari, Italy
[2] II Univ, Naples, Italy
[3] V Fazzi Hosp, Lecce, Italy
[4] Perrino Hosp, Brindisi, Italy
[5] Gen Hosp, Frattamaggiore, Sa, Italy
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 14期
关键词：
D O I：
10.1016/j.ejcsup.2008.06.042
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：121 / 121
页数：1
相关论文
共 50 条
  • [41] Optimal treatment strategy in KRAS wild type (wt) metastatic colorectal cancer (mCRC): Cetuximab plus FOLFIRI followed by FOLFOX4 with or without cetuximab-The Capri trial from the Gruppo Oncologico Dell'Italia Meridionale (GOIM).
    Ciardiello, Fortunato
    Maiello, Evaristo
    Pisconti, Salvatore
    Giuliani, Francesco
    Barone, Carlo
    Rizzo, Mimma
    Bordonaro, Roberto
    Montesarchio, Vincenzo
    Cinieri, Saverio
    Martinelli, Erika
    Troiani, Teresa
    Delcuratolo, Sabina
    Simone, Gianni
    Normanno, Nicola
    Febbraro, Antonio
    Tonini, Giuseppe
    Colucci, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [42] FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study
    Kochi, Mitsugu
    Akiyama, Yuji
    Aoki, Tatsuya
    Hagiwara, Ken
    Takahashi, Takao
    Hironaka, Katsuji
    Teranishi, Futoshi
    Osuka, Fumihiko
    Takeuchi, Masahiro
    Fujii, Masashi
    Nakajima, Toshifusa
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (05) : 1097 - 1102
  • [43] FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study
    Mitsugu Kochi
    Yuji Akiyama
    Tatsuya Aoki
    Ken Hagiwara
    Takao Takahashi
    Katsuji Hironaka
    Futoshi Teranishi
    Fumihiko Osuka
    Masahiro Takeuchi
    Masashi Fujii
    Toshifusa Nakajima
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 1097 - 1102
  • [44] Palonosetron for prevention of acute and delayed nausea and vomiting induced by moderately emetogenic adjuvant folfox-4 regimen in colorectal cancer (CRC) patients: A phase II study of the Gruppo Oncologico dell' Italia Meridionale (GOIM)
    Giuliani, F.
    Cilenti, G.
    Nugnes, I.
    Maiello, E.
    Di Bisceglie, M.
    Lorusso, V.
    Adamo, V.
    Colucci, G.
    EJC SUPPLEMENTS, 2008, 6 (14): : 102 - 106
  • [45] PHASE II TRIAL OF BIWEEKLY ALTERNATING FOLFOX AND FOLFIRI REGIMEN AS FIRST-LINE TREATMENT IN ADVANCED COLORECTAL CANCER (ACC)
    Bernardo, G.
    Palumbo, R.
    Bernardo, A.
    Villani, G.
    Poggi, G.
    Frascaroli, M.
    Jedrychowska, I.
    Delmonte, A.
    Teragni, C.
    Strada, M. R.
    ANNALS OF ONCOLOGY, 2004, 15 : 59 - 59
  • [46] Cisplatin/Pemetrexed Followed by Maintenance Pemetrexed Versus Carboplatin/Paclitaxel/Bevacizumab Followed by Maintenance Bevacizumab in Advanced Nonsquamous Lung Cancer: The GOIM (Gruppo Oncologico Italia Meridionale) ERACLE Phase III Randomized Trial
    Galetta, Domenico
    Cinieri, Saverio
    Pisconti, Salvatore
    Gebbia, Vittorio
    Morabito, Alessandro
    Borsellino, Nicola
    Maiello, Evaristo
    Febbraro, Antonio
    Catino, Annamaria
    Rizzo, Pietro
    Montrone, Michele
    Misino, Andrea
    Logroscino, Antonio
    Rizzi, Daniele
    Di Maio, Massimo
    Colucci, Giuseppe
    CLINICAL LUNG CANCER, 2015, 16 (04) : 262 - 273
  • [47] Cisplatin (CDDP) and Fotemustine (FTM) in Non-Small Cell Lung Cancer (NSCLC) Patients with Brain Metastases (BM): A Multicentric Phase II Study of the Gruppo Oncologico dell'Italia Meridionale (GOIM)
    Galetta, D.
    Gebbia, V.
    Ferrau, F.
    Carrozza, F.
    Cigolari, S.
    Russo, P.
    Calista, F.
    Adamo, S.
    Colucci, G.
    ONCOLOGY, 2009, 77 : 145 - 145
  • [48] First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale
    Gebbia, Vittorio
    Lorusso, Vito
    Galetta, Domenico
    Caruso, Michele M.
    Palomba, Giuseppe
    Riccardi, Fernando
    Borsellino, Nicolo
    Carrozza, Francesco
    Leo, Silvana
    Ferrau, Francesco
    Cinieri, Saverio
    Mancuso, Gianfranco
    Mancarella, Sergio
    Colucci, Giuseppe
    LUNG CANCER, 2010, 69 (02) : 218 - 224
  • [49] First-line cisplatin (P) with docetaxel (TXT) or vinorelbine (VNR) in patients with advanced non-small cell lung cancer: A randomized phase II trial of the Gruppo Oncologico Italia Meridionale
    Gebbia, V.
    Galetta, D.
    Lorusso, V.
    Caruso, M.
    Riccardi, F.
    Maiello, E.
    Borsellino, N.
    Ferrau, F.
    Colucci, G.
    Cinieri, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [50] FIRST-LINE CISPLATIN (P) WITH DOCETAXEL (TXT) OR VINORELBINE (VNR) IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER: A PHASE II RANDOMIZED TRIAL OF GRUPPO ONCOLOGICO ITALIA MERIDIONALE
    Gebbia, V.
    Lorusso, V.
    Galetta, D.
    Caruso, M.
    Maiello, E.
    Riccardi, F.
    Carrozza, F.
    Borsellino, N.
    Leo, S.
    Ferrau, F.
    Cinieri, S.
    Colucci, G.
    EJC SUPPLEMENTS, 2008, 6 (14): : 151 - 151
12345